Recordati S.p.A., a prominent player in the pharmaceutical industry, is headquartered in Luxembourg (LU) and operates extensively across Europe, North America, and other global markets. Founded in 1926, Recordati has established itself as a leader in the development and marketing of innovative medicines, particularly in the fields of rare diseases and specialty pharmaceuticals. The company’s core offerings include a diverse range of prescription drugs, with a strong emphasis on treatments for rare diseases, urology, and cardiovascular conditions. Recordati's commitment to research and development sets it apart, enabling the introduction of unique therapies that address unmet medical needs. With a robust market position, Recordati has achieved significant milestones, including strategic acquisitions and partnerships that enhance its portfolio and global reach.
How does RECORDATI's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
RECORDATI's score of 58 is higher than 73% of the industry. This can give you a sense of how well the company is doing compared to its peers.
In 2024, RECORDATI reported total carbon emissions of approximately 346,511,000 kg CO2e, with Scope 1 emissions at about 37,280,000 kg CO2e, Scope 2 emissions (market-based) at approximately 1,714,000 kg CO2e, and significant Scope 3 emissions totalling around 307,517,000 kg CO2e. This data reflects a comprehensive approach to emissions reporting, including all three scopes. RECORDATI has set ambitious climate commitments, aiming for a 30% reduction in Scope 1 and Scope 2 emissions from a 2021 baseline by 2030. Additionally, they have committed to achieving 100% renewable electricity for their production and packaging sites by 2025. Furthermore, the company has established a target to reduce Scope 1 and Scope 2 greenhouse gas emissions by 42% by 2030 from a 2023 base year, as validated by the Science Based Targets initiative (SBTi). The emissions data is cascaded from their parent company, Recordati Industria Chimica e Farmaceutica S.p.A., ensuring alignment with broader corporate sustainability goals. RECORDATI's ongoing efforts reflect a commitment to addressing climate change and reducing their carbon footprint in line with industry standards.
Access structured emissions data, company-specific emission factors, and source documents
| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|
| Scope 1 | 27,785,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 |
| Scope 2 | 10,302,000 | 00,000,000 | 00,000,000 | 0,000,000 | 0,000,000 | 0,000,000 | 0,000,000 | 0,000,000 | 0,000,000 |
| Scope 3 | - | - | - | - | - | - | - | - | 000,000,000 |
The vast majority of their carbon footprint comes from suppliers and value chain emissions, representing the vast majority of total emissions under the GHG Protocol, with "Purchased Goods and Services" being the largest emissions source at 63% of Scope 3 emissions.
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
RECORDATI has established climate goals through participation in recognized frameworks and target-setting initiatives. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.


Common questions about RECORDATI's sustainability data and climate commitments